Abstract

The opportunistic pathogen Candida albicans is responsible for life-threating infections in immunocompromised individuals. Azoles and polyenes are two of the most commonly used antifungals and target the ergosterol biosynthesis pathway or ergosterol itself. A limited number of clinically employed antifungals correspond to the development of resistance mechanisms. One resistance mechanism observed in clinical isolates of azole-resistant C. albicans is the introduction of point mutations in the ERG11 gene, which encodes a key enzyme (lanosterol 14-α-demethylase) on the ergosterol biosynthesis pathway. Here, we demonstrate that a point mutation K143R in ERG11 (C. albicans ERG11K143R/K143R) contributes not only to azole resistance, but causes increased gene expression. Overexpression of ERG11 results in increased ergosterol content and a significant reduction in plasma membrane fluidity. Simultaneously, the same point mutation caused cell wall remodeling. This could be facilitated by the unmasking of chitin and β-glucan on the fungal cell surface, which can lead to recognition of the highly immunogenic β-glucan, triggering a stronger immunological reaction. For the first time, we report that a frequently occurring azole-resistance strategy makes C. albicans less susceptible to azole treatment while, at the same time, affects its cell wall architecture, potentially leading to exposure of the pathogen to a more effective host immune response.

Highlights

  • IntroductionIn cases of immunodeficiency, it can cause an opportunistic infection called candidiasis [1]

  • Accepted: 28 January 2022Candida albicans (C. albicans) constitutes a natural part of the human microbiome.in cases of immunodeficiency, it can cause an opportunistic infection called candidiasis [1]

  • Considering the importance of ergosterol as a drug target, we investigated the influence of a nonsynonymous point mutation (K143R/K143R) in the ERG11 gene on the plasma membrane (PM) and cell wall (CW) of C. albicans

Read more

Summary

Introduction

In cases of immunodeficiency, it can cause an opportunistic infection called candidiasis [1]. According to a Centers for Disease Control and Prevention (CDC) report, there are approximately 25,000 cases of candidemia (blood infection caused by Candida sp.) each year, and C. albicans remains the dominant species isolated from the patient population [2,3]. Large numbers of Candida-related infections, along with ineffective treatment, lead to a high mortality rate among patients suffering from candidemia (38–75%) [4]. To commonly used antifungals [5]. This is due to widely used antifungals, e.g., azoles, clinically implemented in the 1980s [6]. Decades of azole usage has led to the development of effective defense mechanisms to avoid the toxic activity of antifungals

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call